Biomea Fusion (BMEA) Expected to Post Quarterly Earnings on Tuesday

Biomea Fusion (NASDAQ:BMEA) is expected to release its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect the company to post earnings of ($0.18) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 6, 2026 at 3:00 PM ET.

Biomea Fusion (NASDAQ:BMEA) last issued its quarterly earnings data on Wednesday, August 5th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.10. On average, analysts expect Biomea Fusion to post ($0.65) EPS for the current fiscal year and ($0.71) EPS for the next fiscal year.

Biomea Fusion Price Performance

BMEA opened at $0.64 on Tuesday. The firm has a market capitalization of $46.07 million, a PE ratio of -2.19 and a beta of -0.28. The business’s 50-day moving average is $1.42 and its two-hundred day moving average is $1.39. Biomea Fusion has a 1 year low of $0.55 and a 1 year high of $2.24.

Analysts Set New Price Targets

A number of analysts have recently weighed in on BMEA shares. Citizens Jmp restated a “market outperform” rating and issued a $7.00 price target on shares of Biomea Fusion in a report on Wednesday, October 14th. HC Wainwright reiterated a “buy” rating and set a $4.00 price objective on shares of Biomea Fusion in a research note on Wednesday, October 14th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Biomea Fusion in a research note on Monday, September 28th. Wall Street Zen cut shares of Biomea Fusion from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Brookline Capital Markets initiated coverage on shares of Biomea Fusion in a research report on Wednesday, October 7th. They set a “buy” rating for the company. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $7.60.

About Biomea Fusion

Biomea Fusion, Inc is a clinical-stage biopharmaceutical company focused on developing small-molecule medicines for cancer and metabolic diseases. The company uses its proprietary FUSION System to discover and develop covalent medicines designed to engage disease-relevant protein targets.

Biomea’s lead investigational product is BMF-219, an oral, selective covalent inhibitor of menin. The company has evaluated BMF-219 in clinical studies for certain hematologic malignancies and solid tumors, including acute leukemias and multiple myeloma, and has also investigated its potential in metabolic diseases such as type 2 diabetes.